文献速递血液净化与透析肾血管病与高血压

维生素K2对血液透析患者血管钙化影响的随机对照试验

Randomized Controlled Clinical Trial of the Effect of Treatment with Vitamin K2 on Vascular Calcification in Hemodialysis Patients (Trevasc-HDK).
PubMed 文献 · Kidney Int Rep · 2023-06-22

单中心随机对照试验纳入178例维持性血液透析患者,随机分为维生素K2组(甲萘醌-7 360 μg每周3次)与对照组,随访18个月。主要终点冠状动脉钙化评分两组无统计学差异(RMD 0.85,95%CI 0.55-1.31),维生素K2补充降低了dp-ucMGP水平,但未减少血管钙化进展。

要点

  • 维生素K2 360 μg每周3次补充18个月未显著降低冠状动脉钙化评分。
  • 主动脉瓣钙化、cfPWV、AIx等次要终点两组均无显著差异。
  • 维生素K2组dp-ucMGP水平显著降低,但MACE与死亡复合终点无差异。

核心结论

  • 在本研究剂量和疗程下,维生素K2补充未显示出减少血液透析患者血管钙化进展的获益。

研究设计与样本

  • 单中心随机对照试验,纳入维持性血液透析患者178例,随机分为维生素K2组(甲萘醌-7 360 μg每周3次)与对照组,随访18个月,完成随访138例。

主要发现

  • 18个月末冠状动脉钙化评分两组无统计学差异(RMD 0.85,95%CI 0.55-1.31)。
  • 主动脉瓣钙化两组无显著差异(RMD 0.82,95%CI 0.34-1.98)。
  • cfPWV两组无显著差异(AMD 0.55,95%CI -0.50至1.60)。
  • AIx两组无显著差异(AMD 0.13,95%CI -3.55至3.80)。
  • 维生素K2组dp-ucMGP水平降低(AMD -86,95%CI -854至-117)。

关键数值与推荐

  • 维生素K2组干预为甲萘醌-7 360 μg每周3次。
  • 主要终点为研究结束时冠状动脉钙化评分。
  • 次要终点包括主动脉瓣钙化、cfPWV、AIx、dp-ucMGP、MACE和血管通路事件。

临床怎么用

  • 在本研究剂量和疗程下,维生素K2补充未显示减少血液透析患者血管钙化进展的获益。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Vitamin K deficiency among patients on hemodialysis (HD) affects the function of matrix GLA protein (MGP), a potent vitamin K-dependent inhibitor of vascular calcification (VC). METHODS: We conducted a single-center randomized controlled trial (RCT) on maintenance HD patients to examine if vitamin K2 supplementation can reduce progression of coronary artery calcification (CAC) over an 18-month study period. Patients were randomized to vitamin K2 group receiving menaquinone-7360 μg 3 times/wk or control group. The primary outcome was CAC scores at the end of the study period. The secondary outcomes were aortic valve calcification (AVC), carotid-femoral pulse wave velocity (cfPWV), aortic augmentation index (AIx), dephosphorylated undercarboxylated MGP (dp-ucMGP) levels, major adverse cardiac events (MACE), and vascular access events. RESULTS: Of the 178 patients randomized, follow-up was completed for 138 patients. The CAC scores between the 2 groups were not statistically different at the end of 18 months (relative mean difference [RMD] 0.85, 95% CI 0.55-1.31). The secondary outcomes did not differ significantly in AVC (RMD 0.82, 95% CI 0.34-1.98), cfPWV (absolute mean difference [AMD] 0.55, 95% CI -0.50 to 1.60), and AIx (AMD 0.13, 95% CI -3.55 to 3.80). Supplementation with vitamin K2 did reduce dp-ucMGP levels (AMD -86, 95% CI -854 to -117). The composite outcome of MACE and mortality was not statistically different between the 2 groups (Hazard ratio = 0.98, 95% CI 0.50-1.94). CONCLUSION: Our study did not demonstrate a beneficial effect of vitamin K2 in reducing progression of VC in this population at the studied dose and duration.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Haroon S, Davenport A, Ling LH, et al. Randomized Controlled Clinical Trial of the Effect of Treatment with Vitamin K2 on Vascular Calcification in Hemodialysis Patients (Trevasc-HDK). Kidney Int Rep. 2023. PMID: 37705910. doi:10.1016/j.ekir.2023.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。